Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-394-2 | CAS number: 3085-30-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / bone marrow chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- publication
- Title:
- Evaluation of genotoxic effects of oral exposure to aluminum oxide nanomaterials in rat bone marrow
- Author:
- Balasubramanyam A, Sailaja N, Mahboob M, Rahman MF, Misra S, Hussain SM, Grover P.
- Year:
- 2 009
- Bibliographic source:
- Mutation Research 676 (1-2): 41-47.
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 475 (Mammalian Bone Marrow Chromosome Aberration Test)
- Deviations:
- not specified
- GLP compliance:
- not specified
- Type of assay:
- chromosome aberration assay
Test material
- Reference substance name:
- Aluminium oxide
- EC Number:
- 215-691-6
- EC Name:
- Aluminium oxide
- IUPAC Name:
- aluminium oxide
Constituent 1
- Specific details on test material used for the study:
- purity > 90%
particle size: 50-200 um
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: W NIN (National Institute of Nutrition, Hyderabad, India).
- Age at study initiation: 4-5 weeks old
- Weight at study initiation: 90-100 g
- Diet: ad libitum. The feed was described as standard laboratory feed (wheat flour 2.5%; roasted Bengal gram flour 60%; skimmed milk powder 5%; casein 4%; refined ground oil 4%; salt mixture 4%; vitamin mixture 0.5%).
- Water: ad libitum
- Acclimation period: 1 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3ºC
- Humidity (%): no data
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12-h light/dark cycles
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: DDW-Tween 80 (1%) mixture
- Volume dosed: No data - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Al2O3 was suspended in 1% Tween 80 (a surfactant that enhances uptake), dispersed by ultrasonic vibration for 10 minutes and “mixed thoroughly” prior to use. - Duration of treatment / exposure:
- 14 days
- Frequency of treatment:
- acute exposure (expected to be daily)
- Post exposure period:
- CA assay: 18h, 24 h
Mitotic Index (MI): 18h, 24h
Al Level Study:
Urine and faeces: 48 h after (first?) dosing
Blood and tissues (liver, spleen, heart, kidneys and brain): on day 14 at sacrifice
Doses / concentrationsopen allclose all
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Remarks:
- as Al2O3; 265 mg/kg bw as Al
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- as Al2O3; 529 mg/kg bw as Al
- Dose / conc.:
- 2 000 mg/kg bw/day (nominal)
- Remarks:
- as Al2O3; 1069 mg/kg bw as Al
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Substance: Cyclophosphamide
Justification: Known mutagen on list of acceptable positive control substances in the relevant OECD TGs.
Route of administration: intraperitoneal
Dose/concentration: 40 mg/kg bw, volume = 0.01 mL/g bw
Examinations
- Tissues and cell types examined:
- Rat bone marrow.
- Details of tissue and slide preparation:
- CA Assay:
The authors stated that the measurements were made in accordance with OECD TG#475. 500 well-spread metaphases (100 per animal) were analyzed for each treatment (dose/time). Aneuploidy, polyploidy, gaps, breaks, minutes, acentric fragments and reciprocal translocations were counted.
Al-Levels:
0.1 - 0.3 g of fresh tissue were predigested in ultrapure nitric acid overnight, heated to 80 ºC for 10 h and then 130 - 150 ºC for 30 minutes. The samples were then heated (temperature not provided) for an additional 4 hours in the presence of 0.5 mL 70% perchloric acid and evaporated to dryness. Solutions were then made up to 5 mL with deionized water, filtered and the Al concentration was determined using ICP-MS with rhodium at 20 ng/mL as an internal standard.
Cytotoxicity (Mitotic Index)
The MI was determined on 1000 cells or more from randomly selected slides that were coded prior to scoring. - Evaluation criteria:
- According to guideline.
- Statistics:
- The methods used were included in the article but were not well-described. The LSD-test mentioned in the article is more appropriate for particular planned comparisons and not for comparing several pairs of means. Testing for homogeneity of variances was also not mentioned. The results show some evidence of an increase in the magnitude of the standard deviation with dose for some endpoints.
Results and discussion
Test results
- Key result
- Sex:
- female
- Genotoxicity:
- negative
- Remarks:
- CA Assay: Al2O3 - (50-200 μm)
- Toxicity:
- no effects
- Remarks:
- The authors briefly mention that no mortality nor toxic symptoms were observed at any dose level in the range-finding study (OECD TG #420) nor in the 5 rats at the highest dose level in the main study that was reported in the article.
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- MI: There was no significant reduction in MI at either sampling time for any of the dose groups compared with the vehicle control.
At 18h:
Negative control: 2.97(±0.12)
Treated groups: The MI ranged from 91 to 110% of the value in the negative control.
Positive control: 75% of negative control
At 24h:
Negative control: 3.25±0.10 (mean, sd)
Treated groups: The MI ranged from 82 to 90% of the value in the negative control.
Positive control: 80% of negative control
General toxicity: The authors briefly mention that no mortality nor toxic symptoms were observed at any dose level in the range-finding study (OECD TG #420) nor in the 5 rats at the highest dose level in the main study that was reported in the article.
Any other information on results incl. tables
CA assay:
Total aberrations (excluding gaps)
Negative control (1% Tween 80), mean (±sd)
18h: 0.6(±0.32)
24h: 0.5(±
0.42)
Al2O3- (50-200 μm)
18h:
25 mg Al:0.6±0.22 - ns
50 mg Al: 2.2±0.79 - ns
100 mg Al: 4.3±1.01 - ns
24h:
25 mg Al:0.5±0.31 - ns
50 mg Al: 1.2±0.51 - ns
100 mg Al: 5.5±0.31 - ns
- No polyploidy or reciprocal translocations observed in the Al-treated groups;
- Aneuploidy: clear dose response (not statistically tested for trend) observed for the 30 nm and 40 nm groups with significantly higher numbers in the highest dose group (p<0.001). Al-levels: “Al-content”μgAl2O3/g wet tissue:
Al Levels
Control (units±sd)
Whole blood 3±1 μg/g
Liver 6±2μg/g
Spleen 2±1μg/g
Heart 6±3 μg/g
Kidneys 9±4 μg/g
Brain 2±3 μg/g
Urine (48 hours post-dosing) 5±2 μg/mL
Faeces (48 hours post-dosing) 1±1 mg/g
Al2O3- (50-200 μm)”bulk”
The levels in tissues show an increase with dose that does not reach statistical significance. A significant (p<0.01) increase in the Al2O3content in faeces relative to the control was observed at 2000 mg/kg bw. The amounts of Al in tissues of the nanomaterial dosed animals were much higher than those found in animals dosed with the bulk material.
A particle size dependence of gastrointestinal absorption was apparent with lower levels in the tissues reported for the larger 50 to 200 μm diameter particles (Al2O3-bulk). The levels of Al in the Al2O3-bulk treated groups showed an increase but were not reported as significantly different from the controls. The reported levels of Al in the urine of the control group were three orders of magnitude greater than “normal” levels in humans.
Applicant's summary and conclusion
- Conclusions:
- No significant increase in the number of aberrations. Therefore it can be concluded that Al2O3 does not exhibity clastogenic effects under the conditions of the test
- Executive summary:
Balasubramanyam et al. (2009a) administered suspensions of aluminium oxide by oral gavage to female albino Wistar rats (5 animals per group). Concentrations of 500, 1000 and 2000 mg Al2O3/kg bw in 1% Tween 80/doubly-distilled water (DDW) were administered to the rats. These concentrations are equivalent to 265, 529 and 1059 mg Al/kg bw. Three size fractions of aluminium oxide particles were examined: Al2O3 (30 nm; transmission electron microscopy (TEM) determined diameter, mean±sd - 39.85±31.33 nm), Al2O3 (40 nm; TEM diameter, mean±sd – 7.33±36.13 nm), and Al2O3-bulk (diameter 50 to 200μm). A negative control group was treated orally with the Tween 80/DDW vehicle.A positive control group received a single intraperitoneal dose of 40 mg/kg bw of cyclophosphamide. The assessment of CA in bone marrow cells was conducted in accordance with OECD Test Guideline #475 with the analysis of 500 well-spread metaphases (100 per animal) for each treatment 18 and 24 hours after the last dosing. Aneuploidy, polyploidy, gaps, breaks, minutes, acentric fragments and reciprocal translocations were counted. The mitotic index was determined on 1000 cells at both sampling times, slides were selected randomly and coded to blind analysts. Dose levels were determined using an acute oral toxicity study conducted in accordance with OECD Test Guideline #420. Organ tissue was analyzed for aluminium content by ICP-MS (inductively coupled mass spectrometry). The LSD-test mentioned in the article is more appropriate for particular planned comparisons and not for comparing several pairs of means. There was no indication of an effect of treatment on the mitotic index.
Eighteen hours after the final dosing, the mean±sd total aberrations for the control, 265, 529 and 1058 mg Al/kg bw/day Al2O3-bulk groups were 0.6±0.3, 0.6±0.3, 2.2±0.8, and 4.3±1.0, respectively. Statistical testing reported in the article indicated no significant differences for any treatment level of this group compared with the control group. The reported measurements of levels of Al in the urine and faeces sampled 48 hours after dosing and in tissues in samples taken on day 14 were reported as μg Al2O3/g wet tissue (clarified after contact with the author). Aluminium levels were elevated in all tissues in a dose-response manner with either of the nano-sized particulates. A particle size dependence of gastrointestinal absorption was apparent with lower levels of aluminium in the tissues reported for the larger 50 to 200 μm diameter particles (Al2O3-bulk). The levels of Al in the Al2O3-bulk treated groups showed an increase but were not reported as significantly different from the controls. The measurements do, however, show consistent increases inlevels of Al in tissues and organs with increasing dose.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.